Cellumed Accelerates Next-Generation Bone Graft Development with AI... Identifies Eight New Peptide Candidates

Cellumed, a company specializing in bio-medical devices, is accelerating its research on next-generation bone graft materials by utilizing artificial intelligence (AI).

Cellumed announced on September 22 that it began research in July on developing AI-based peptide fusion bone graft materials. By leveraging AI technology, the company was able to significantly shorten the candidate discovery process-which typically takes six to seven months-and identified eight new candidate substances. During this process, the research utilized AlphaFold 3, the latest protein structure prediction platform developed by Google DeepMind.

Throughout the research, Cellumed focused on analyzing the protein structures of BMP2 and growth factors, as well as examining binding interactions and verifying the binding strength and stability of peptide candidates designed with novel structures (de novo design). The eight candidate substances discovered are currently undergoing further validation and will be refined into key candidates through an optimization phase. The company plans to finalize the core candidates within the year and begin efficacy studies using animal models.

A Cellumed representative stated, "By combining AlphaFold 3 with our research expertise, we were able to greatly enhance the efficiency of candidate discovery," adding, "This research marks an important milestone in developing next-generation bone graft materials aimed at improving the osteogenic ability and biocompatibility of demineralized bone matrix (DBM)."

Additionally, Cellumed plans to gradually expand the application of AI-based research and development to all applicable stages based on this achievement. The company explained, "AI technology is an innovative tool that enhances research efficiency and enables the rapid identification of promising substances," and added, "We will continue to actively integrate AI-based approaches to steadily strengthen the competitiveness of tissue bank-based graft research, including skin and bone."

Meanwhile, Cellumed primarily manufactures the orthopedic bone graft material "Rafugen DBM (Demineralized Bone Matrix)" and the dental bone graft material "Rafugen Dental." Since the beginning of this year, the company has more than doubled its production capacity through a 'production process TFT,' resulting in approximately an 85% increase in related sales compared to the same period last year as of August.

This content was produced with the assistance of AI translation services.